Live feed16:30:00·220dPRReleasevia QuantisnowTECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomideByQuantisnow·Wall Street's wire, on your screen.JNJ· Johnson & JohnsonHealth Care
